Compare IPCA Labs with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DISHMAN PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DISHMAN PHARMA IPCA LABS/
DISHMAN PHARMA
 
P/E (TTM) x 22.9 25.1 91.4% View Chart
P/BV x 4.4 3.3 132.9% View Chart
Dividend Yield % 0.1 0.7 15.9%  

Financials

 IPCA LABS   DISHMAN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
DISHMAN PHARMA
Mar-16
IPCA LABS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs695374 185.7%   
Low Rs400129 310.3%   
Sales per share (Unadj.) Rs260.2197.8 131.5%  
Earnings per share (Unadj.) Rs19.021.2 89.5%  
Cash flow per share (Unadj.) Rs33.134.7 95.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.8 23.0%  
Book value per share (Unadj.) Rs213.0179.9 118.4%  
Shares outstanding (eoy) m126.2080.69 156.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.3 165.5%   
Avg P/E ratio x28.911.9 243.3%  
P/CF ratio (eoy) x16.67.2 228.6%  
Price / Book Value ratio x2.61.4 183.8%  
Dividend payout %5.39.4 55.9%   
Avg Mkt Cap Rs m69,12020,306 340.4%   
No. of employees `00013.30.8 1,598.8%   
Total wages/salary Rs m7,3595,355 137.4%   
Avg. sales/employee Rs Th2,477.419,252.7 12.9%   
Avg. wages/employee Rs Th555.26,459.5 8.6%   
Avg. net profit/employee Rs Th180.62,064.1 8.8%   
INCOME DATA
Net Sales Rs m32,83615,961 205.7%  
Other income Rs m418265 157.5%   
Total revenues Rs m33,25416,226 204.9%   
Gross profit Rs m4,5054,103 109.8%  
Depreciation Rs m1,7771,091 163.0%   
Interest Rs m240944 25.4%   
Profit before tax Rs m2,9052,334 124.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511624 82.0%   
Profit after tax Rs m2,3941,711 139.9%  
Gross profit margin %13.725.7 53.4%  
Effective tax rate %17.626.7 65.8%   
Net profit margin %7.310.7 68.0%  
BALANCE SHEET DATA
Current assets Rs m19,45511,018 176.6%   
Current liabilities Rs m10,0769,517 105.9%   
Net working cap to sales %28.69.4 303.7%  
Current ratio x1.91.2 166.8%  
Inventory Days Days98110 88.6%  
Debtors Days Days6735 192.2%  
Net fixed assets Rs m20,26016,304 124.3%   
Share capital Rs m252161 156.4%   
"Free" reserves Rs m26,63312,907 206.4%   
Net worth Rs m26,88614,516 185.2%   
Long term debt Rs m2,3404,189 55.9%   
Total assets Rs m41,17329,805 138.1%  
Interest coverage x13.13.5 377.3%   
Debt to equity ratio x0.10.3 30.2%  
Sales to assets ratio x0.80.5 148.9%   
Return on assets %6.48.9 71.8%  
Return on equity %8.911.8 75.5%  
Return on capital %10.817.5 61.4%  
Exports to sales %47.624.8 192.2%   
Imports to sales %14.93.7 398.1%   
Exports (fob) Rs m15,6423,956 395.4%   
Imports (cif) Rs m4,884596 819.0%   
Fx inflow Rs m15,6424,952 315.9%   
Fx outflow Rs m4,884697 700.9%   
Net fx Rs m10,7594,255 252.9%   
CASH FLOW
From Operations Rs m3,4112,786 122.4%  
From Investments Rs m-1,354-1,529 88.6%  
From Financial Activity Rs m-1,304-941 138.6%  
Net Cashflow Rs m753316 238.1%  

Share Holding

Indian Promoters % 45.9 61.4 74.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 3.7 308.1%  
FIIs % 25.3 12.7 199.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 22.1 78.7%  
Shareholders   36,892 46,261 79.7%  
Pledged promoter(s) holding % 2.1 35.8 6.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Oct 18, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS